(Q38388102)

2 September 2017

1 reference

title

Immunotherapeutic approaches for cancer therapy: An updated review (English)

1 reference

2 September 2017

1 reference

Farhad Jadidi-Niaragh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25801036%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Mehdi Yousefi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25801036%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Tohid Kazemi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25801036%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Vahid Younesi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25801036%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

24 March 2015

1 reference

Artificial cells, nanomedicine, and biotechnology

2 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25801036%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25801036%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25801036%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

769-779

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25801036%20AND%20SRC:MED&resulttype=core&format=json

Interferon in the treatment of hairy-cell leukemia

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Current developments of immunotherapy in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Immunogenicity of protein therapeutics: The key causes, consequences and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Tumour escape mechanisms and their therapeutic implications in combination tumour therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Strategy for the production of human monoclonal antibodies using in vitro activated B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Chimeric antigen receptor-engineered T cells for immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Development of a whole cell vaccine for acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Safety profile of recombinant canarypox HIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

DNA vaccines: progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Molecular biology of human papillomavirus infection and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

GM-CSF-secreting melanoma vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Viruses as vaccine vectors for infectious diseases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Targeting leukemic stem cells by breaking their dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Human tumor antigens, immunosurveillance, and cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Prevention of cancer through immunization: Prospects and challenges for the 21st century.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Viral vectors for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Clinical cancer vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Replacing the complementarity-determining regions in a human antibody with those from a mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Gene-engineered T cells for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Cancer immunoediting from immune surveillance to immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Cancer immunotherapy: the interferon-alpha experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Checkpoint blocking antibodies in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Can successful vaccines teach us how to induce efficient protective immune responses?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Vaccination with allogeneic GM-CSF gene-modified lung cancer cells: antitumor activity comparing with that induced by autologous vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Vaccines for tumour prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Fully human antibodies from transgenic mouse and phage display platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Vaccinia virus: a selectable eukaryotic cloning and expression vector

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Use of bacille Calmette-Guérin in superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Resiquimod, a topical drug for viral skin lesions and skin cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Anti-CD137 antibodies in the treatment of autoimmune disease and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Part I: Vaccines for solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Interleukin-10 and the immune response against cancer: a counterpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Cancer vaccines: the next generation of tools to monitor the anticancer immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

A hapten-specific chimaeric IgE antibody with human physiological effector function.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Assessment of risk of cancer after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Microparticle-based technologies for vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Imiquimod: in superficial basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Dendritic-cell-based therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Autologous versus allogeneic cell-based vaccines?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Role of transforming growth factor beta in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Modulating CD27 signaling to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

DNA vaccines for viral infections: basic studies and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

The basic principles of chimeric antigen receptor design

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Interleukin-10: a cytokine used by tumors to escape immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Modulation of GITR for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Neoplastic stem cells: current concepts and clinical perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Epitope landscape in breast and colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

The rationale for prophylactic cancer vaccines and need for a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Immunotherapy for human cancer using heat shock protein-peptide complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Taking dendritic cells into medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

DNA vaccines and adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

DNA vaccines to attack cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Therapeutic dendritic cell-based cancer vaccines: the state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Challenges for cancer vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Genetic immunization is a simple method for eliciting an immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Targeting p53 as a general tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Immunotherapy of cancer with 4-1BB.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Trastuzumab: updated mechanisms of action and resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Cancer vaccines: Looking to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Adoptive T-cell therapy for cancer: boutique therapy or treatment modality?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

DNA vaccines for cancer too.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F21691401.2015.1019669

10.3109/21691401.2015.1019669

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25801036%20AND%20SRC:MED&resulttype=core&format=json

release_k7cn44fkfjf53a5azhtvsopjhi

7 June 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/k7cn44fkfjf53a5azhtvsopjhi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference